Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Rituxan (rituximab) Intravenous Injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – February 2012

 

Summary View

 

Warnings and Precautions

Infections
  • Infections have been reported in some patients with prolonged hypogammaglobulinemia (defined as hypogammaglobulinemia >11 months after rituximab exposure).
 

ADVERSE REACTIONS

Postmarketing Experience
Hematologic:  
  • prolonged hypogammaglobulinemia
 

MEDICATION GUIDE

“What are the possible side effects of Rituxan”
  • infections with multiple types of pathogens.
-
-